Erlotinib + Chemotherapy
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Jan 1, 2014 → Dec 1, 2014
NCT ID
NCT02000531About Erlotinib + Chemotherapy
Erlotinib + Chemotherapy is a approved stage product being developed by Roche for Carcinoma, Non-Small-Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT02000531. Target conditions include Carcinoma, Non-Small-Cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-Small-Cell Lung were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02064491 | Phase 2 | Completed |
| NCT02000531 | Approved | Completed |
| NCT01342965 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung